SCHEMBL20249342

SCHEMBL20249342

CC(O)CN1CCN(c2ccc(C(C)(C)C)nc2)C(=O)C1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.35
PARP2 Q9UGN5 1/20 0.35
HRH3 Q9Y5N1 1/20 0.33
PIK3CD O00329 1/20 0.33
KCNH2 Q12809 2/20 0.33
DRD3 P35462 2/20 0.33
CDK4 P11802 2/20 0.33
CCND1 P24385 2/20 0.33
CDK2 P24941 2/20 0.33
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
BRD4 O60885 1/20 0.32
REN P00797 1/20 0.32
PPARD Q03181 1/20 0.32
PPARA Q07869 1/20 0.32
DRD2 P14416 1/20 0.31
DRD4 P21917 1/20 0.31
SLC6A3 Q01959 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249300 0.91 PIK3CD (0.43) PARP1PARP2HRH3PIK3CDKCNH2
SCHEMBL20249440 0.90 KCNH2 (0.35) PARP1PARP2HRH3KCNH2DRD3
SCHEMBL20249457 0.90 KCNH2 (0.35) PARP1PARP2HRH3KCNH2DRD3
SCHEMBL20249309 0.83 GAA (0.37) PARP1PARP2HRH3KCNH2DRD3
SCHEMBL20249326 0.83 AR (0.36) PARP1PARP2HRH3KCNH2DRD3
SCHEMBL20255524 0.83 PIK3CD (0.35) HRH3PIK3CDKCNH2DRD3CDK4
SCHEMBL20249319 0.83 DRD3 (0.35) PARP1PARP2HRH3KCNH2DRD3
SCHEMBL20249369 0.81 ALDH1A1 (0.38) PARP1PARP2HRH3KCNH2DRD3
SCHEMBL20249324 0.80 NPC1 (0.42) PIK3CD
SCHEMBL20249366 0.80 ALDH1A1 (0.36) PARP1PARP2HRH3KCNH2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 PARP1 819/4885PARP2 1278/4885HRH3 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.